Staar Surgical CoSTAA -2.18%81 Buyback Yield % is 0.59 as of Jul. 01, 2026, which is 638% above its 10-year median of 0.08. GuruFocus rates STAA with a GF Score™ of 81/100 and a GF Value™ of $31.39 (Fairly Valued). The stock has 7 warning signs investors should review. Among 345 Medical Devices & Instruments companies, Staar Surgical Co ranks better than 75.36% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Staar Surgical Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STAA vs BLFS, ATRC, KMTS: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staar Surgical Co Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staar Surgical Co (STAA) has a Buyback Yield % of 0.59 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Staar Surgical Co and its competitors. This is 638% above median its historical median of 0.08. According to the industry distribution chart, Staar Surgical Co ranks #85 out of 345 companies in the Medical Devices & Instruments industry, placing it in the top 24.6%.
Is Staar Surgical Co's Buyback Yield % too high?
Staar Surgical Co's current Buyback Yield % of 0.59 is 638% above median its 10-year median of 0.08. Based on the distribution chart, Staar Surgical Co ranks #85 out of 345 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Staar Surgical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's Buyback Yield % compare to BLFS and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Staar Surgical Co ranks #85 out of 345 companies for Buyback Yield %. This places Staar Surgical Co in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Staar Surgical Co and its competitors. Staar Surgical Co's current Buyback Yield % is 0.59, which is 638% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (STAA) is currently considered Fairly Valued. The stock's GF Value™ is $31.39, compared to a current price of $28.70 — trading 8.6% below its estimated fair value. The current Buyback Yield % is 0.59, which is 638% above median its 10-year median of 0.08. Staar Surgical Co's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Staar Surgical Co (STAA), the current Buyback Yield % is 0.59 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staar Surgical Co (STAA) Overvalued in 2026?
Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued.
The current stock price of $28.70 is trading 8.6% below its estimated GF Value™ of $31.39.
GuruFocus considers Staar Surgical Co to be Fairly Valued.
Key valuation signals for STAA:
Buyback Yield %: 0.59 (638% above median its 10-year median of 0.08)
GF Value™: $31.39 vs. price of $28.70 (8.6% below fair value)
No single metric tells the full story. See the STAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
81GF Score
Get the complete analysis for STAA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STAA has been successfully added to your 
